加载中
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
前收盘价
US$4.05
−US$0.06 · -1.46%
盘后
US$4.0299
−US$0.0201 · -0.50%
10月12日 19:53 ET
盘中时间采用ET。市场数据可能有所延迟。
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
日内区间
当前US$4.05
52周区间
当前US$4.05
盘中时间采用ET。市场数据可能有所延迟。
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
日内区间
当前US$4.05
52周区间
当前US$4.05
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 67.5万 USD | 95.1万 USD | — |
| 销货成本 | 57.2万 USD | — | — | — | — |
| 毛利 | −57.2万 USD | — | 67.5万 USD | 95.1万 USD | — |
| 研究与开发 | 912.1万 USD | 2001.4万 USD | 1290.2万 USD | 1243.6万 USD | 608万 USD |
| 销售、一般及管理费用 | 2039.6万 USD | 1210.3万 USD | 854.7万 USD | 656.7万 USD | 289.7万 USD |
| 营业费用 | 2894.5万 USD | 3211.7万 USD | 2144.9万 USD | 1900.3万 USD | 897.7万 USD |
| 利息收入 | 101.2万 USD | 126.1万 USD | 61.5万 USD | — | — |
| 利息支出 | 7.1万 USD | 7.1万 USD | 8.2万 USD | 6000 USD | 62.8万 USD |
| 折旧和摊销 | 57.2万 USD | 42.8万 USD | 28.4万 USD | 16.1万 USD | 1.3万 USD |
| 营业利润 | −2951.7万 USD | −3211.7万 USD | −2077.4万 USD | −1805.2万 USD | −897.7万 USD |
| 净利润 | −2655.5万 USD | −3672.9万 USD | −3054.4万 USD | −1805.8万 USD | −1001.7万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$22.00
上涨空间 443.21%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI418.97万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM256.72万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF124.81万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO82.6万0.01%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO73.07万0.00%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS32.32万0.00%338.04亿 USD0.31%US$78.17-0.23%
iShares Micro-Cap ETFIWC31.92万0.02%13.17亿 USD0.60%US$181.66-0.73%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC17.58万0.02%10.49亿 USD0.20%US$86.26-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
